CANTON, Mass., March 27, 2012 /PRNewswire/ –Today MassBio members elected Geoff MacKay, president & CEO of regenerative medicine leader Organogenesis Inc., as chairman of the board of directors at the 2012 MassBio Annual Meeting. (Photo: http://photos.prnewswire.com/prnh/20120327/NE76866) During this year’s meeting, MassBio members also elected three new board members: Caren Arnstein, senior vice president and Head of Communications for Genzyme, James Hoyes, President of EMD Serono, Inc., and David Lucchino, CEO of Semprus BioSciences. MacKay will serve a two-year term as board chair
Medicine’s recipe for keeping older people active and functioning in their homes and workplaces – and healing younger people injured in catastrophic accidents – may include “noodle gels” and other lab-made invisible filaments that resemble uncooked spaghetti with nanoscale dimensions, a scientist said here today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS).
Washington, Mar 26 (ANI): Medicine's recipe for keeping older people active and functioning in their homes and workplaces and healing younger people injured in catastrophic accidents may include “noodle gels” and other lab-made invisible filaments that resemble uncooked spaghetti with nanoscale dimensions, a scientist has claimed.
22-03-2012 12:16 Dr. Victor Dzau is a physician and pioneering translational research scientist, and is widely recognized as one of the most influential medical leaders worldwide. He is currently the James B.
Weve heard of people freezing their eggs, blood and stem cells for use later on, but a health service startup is now enabling patients to freeze their own skin cells for potential future use in diagnostics, therapeutics and regenerative medicine techniques. Next Healthcare Inc.s goal is to enable personalized healthcare by providing skin and stem cell banking directly to patients through their medical professional
WINSTON-SALEM, N.C., March 19, 2012 /PRNewswire/ — Tengion, Inc. (NASDAQ: TNGN – News), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 26, 2012, at 5:00 p.m. EDT to provide a business update and discuss its fourth quarter 2011 financial results.
28-12-2011 05:37 Ceraxon Citicoline – link to online store GenuineTabs.com Modafinil (Modalert) 100 mg / 200 mg Modalert (modafinil) is a medication that promotes wakefulness. It is thought to work by altering the natural chemicals (neurotransmitters) in the brain.
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that on Monday, March 12 it filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock
Organogenesis Inc. of Canton, a leader in the regenerative medicine field, announced today its product, Gintuit, which is designed to form new gum tissue for dental patients, has been approved by the U.S. Food and Drug Administration
Robert Shaw, left, commercial director of EMD Millipores Stem Cell Initiative, and Michael May, CEO of the Centre for Commercialization of Regenerative Medicine in Toronto. EMD Millipore, the Billerica-based life science division of Merck KGaA, said today that it is collaborating with the Centre for Commercialization of Regenerative Medicine in Toronto to develop optimized conditions to cultivate stem cells in a bioreactor. The two parties will focus on developing a proprietary monitoring and control methodology for robust growth of adherent human pluripotent stem cells in EMD Millipores Mobius CellReady stirred tank bioreactor
Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue). The GINTUIT approval marks two important firsts: the first-ever approval of an allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA, and the first cell-based technology that is FDA-approved for use in the dental market.
More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital Posted March 12, 2012 FDA Approval Marks First-Ever CBER-Approved Allogeneic Cell-Based Product CANTON, Mass., — Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUITTM (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue). The GINTUIT approval marks two important firsts: the first-ever approval of an allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA, and the first cell-based technology that is FDA-approved for use in the dental market.
CLEARWATER, FL–(Marketwire -03/12/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK – News) (Pinksheets: BOSM.PK – News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of cardiothoracic surgeon Thomas W. Prendergast, M.D. to its Scientific and Medical Board of Advisors (SAMBA).